• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»injectable aesthetics

How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction

By Pallavi Madhiraju on March 23, 2026   Pharma & Biotech  

How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction

FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.

How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine

By Pallavi Madhiraju on February 12, 2026   Pharma & Biotech  

How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine

Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.

How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences

By Pallavi Madhiraju on January 30, 2026   Pharma & Biotech  

How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences

Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes